IDH1 and astrocytoma (excluding glioblastoma): In a clinical trial (NCT02454634) evaluating the IDH1-specific vaccine in patients with IDH1(R132H) + astrocytoma, vaccine-related side effects were limited to grade 1, and no significant toxicity that would impact the treatment regimen was observed.